Ariad submits EU MAA for ponatinib and prepares to storm Europe
This article was originally published in Scrip
Executive Summary
Ariad Pharmaceuticals has submitted its marketing authorisation application to the European Medicines Agency for ponatinib for resistant or intolerant chronic myeloid leukaemia and Philadelphia-chromosome positive acute lymphoblastic leukaemia. Tim Clackson, the firm's CSO and president of R&D, explained how Ariad will makes it name in the European oncology market and why partnering is not the way to do it.
You may also be interested in...
Italy To Consult On Pricing Transparency Requirements
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.
German Guidelines Seek To Boost Biosimilar Uptake
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.
European Regulatory Strategy ‘Should Prioritize Real World Evidence’
EFPIA, the European Federation of Pharmaceutical Industries and Associations, has put forward what it thinks the European regulatory network strategy to 2025 should prioritize.
Need a specific report? 1000+ reports available
Buy Reports